Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: A 9-year study at Princess Noorah Oncology Center, Saudi Arabia

Histopathology

Volumn 59, Issue 3, 2011, Pages 537-542

  Satti, Mohamed B ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Breast cancer; Human epidermal growth factor receptor 2; Oestrogen receptor; Progesterone receptor; Saudi Arabia

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; APOCRINE CARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER SIZE; CARCINOMA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LOBULAR BREAST CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDULLARY CARCINOMA; METAPLASTIC CARCINOMA; MUCINOUS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAUDI ARABIA; SCORING SYSTEM; SECRETORY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM GRADING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SAUDI ARABIA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80053324868     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03883.x     Document Type: Article

References (27)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2; 533-543.
2. Saudi Arabian National Cancer Registry. Saudi Arabia: Ministry of Health Publications, 1999.
3. Ezzat AA, Ibrahim EM, Raja MA, Al Sobhi S, Rostom A, Stuart RK. Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med. Oncol. 1999; 16; 95-103.
4. Harvey JM, Clark EM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999; 17; 1474-1481.
5. American Society of Clinical Oncology (ASCO) Tumor Marker Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 1996; 14; 2843-2877.
6. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J. Natl Cancer Inst. 1991; 83; 154-155. [Editorial].
7. Salmon DJ, Clark EM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-neu oncogene. Science 1987; 235; 177-182.
8. Press M, Bernstein L, Thomas PA et al. HER2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 1997; 15; 2894-2904.
9. Menard S, Valagussa P, Pilotti S et al. Response to cyclophosphamide, methotrexate and fluorouracil in lymph node positive breast cancer according to HER2 overexpression and other tumor biologic variables. J. Clin. Oncol. 2001; 19; 329-335.
10. Pritchard KL, Shepher LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 2006; 354; 2103-2111.
11. Salmon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344; 783-792.
12. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002; 20; 719-726.
13. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005; 353; 1673-1684.
14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006; 354; 809-820.
15. Bast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for use of tumor markers in breast and colorectal cancer. Clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001; 19; 1865-1878.
16. American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP). Recommendation for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007; 131; 18-43.
17. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br. J. Cancer 1957; 11; 359-377.
18. Tavassoli FA, Devilee P World Health Organization classification of tumours: tumours of the breast and female genital organs. Lyon: IARC Press, International Agency for Research on Cancer, 2003; 18-19.
19. Allred DC, Harvey JM, Berardo M et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11; 155-168.
20. Bardou VJ, Arpino G, Elledge RM et al. Progesterone receptor studies significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 2003; 21; 1973-1979.
21. Hammond MEH, Hayes DF, Dowsett M et al. ASCO/CAP guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 2010; 134; E1-E16.
22. Gown AM. Current issues in ER and HER2 testing by IHC. Mod. Pathol. 2008; 21; S8-S15.
23. Allred DC. Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer. Mod. Pathol. 2010; 23; S52-S59.
24. Nadji M, Gomez-Fernandez C, Ganjei-Azar P et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5993 breast cancers. Am. J. Clin. Pathol. 2005; 123; 21-27.
25. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
26. Brenton JD, Carey LA, Ahmed AA et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J. Clin. Oncol. 2005; 23; 7350-7360.
27. Al-Tamimi DM, Bernard PS, Shawarby MA, Al-Amri AM, Hadi MA. Distribution of molecular breast cancer subtypes in middle eastern-saudi arabian women: a pilot study. Ultrastruct. Pathol. 2009; 33; 141-150.